Piperidinylamino tricyclic compounds as substance P antagonists
AssigneePfizer Inc.
InventorsHiroki Koike, Hiroaki Wakabayashi
Life of this patent
Estimating the term…
Loading patent…
AssigneePfizer Inc.
InventorsHiroki Koike, Hiroaki Wakabayashi
Estimating the term…
This invention provides a compound of the formula: ##STR1## and its pharmaceutically acceptable salts, wherein Ar.sup.1 is selected from the group having the formulae: ##STR2## wherein, R.sup.1 and R.sup.2 are independently hydrogen or C.sub.1 -C.sub.6 alkyl; W is (CH.sub.2).sub.a wherein n is from 1 to 3, or --CH.dbd.CH--; X is C.sub.1 -C.sub.6 alkoxy or halo C.sub.1 -C.sub.6 alkoxy; and Ar.sup.2 is phenyl optionally substituted by halogen atom. These compounds are useful in the treatment of a gastrointestinal disorder, a central nervous system (CNS) disorder, an inflammatory disease, emesis, urinary incontinence, pain, migraine, sunburn, angiogenesis, diseases, disorders and adverse conditions caused by Helicobacter pylori, or the like in a mammalian subject, especially humans.
A compound of the formula (I):
Dependencies are inferred from the claim text.